CombiGene’s CEO: “I am looking forward to meeting more potential partners”
CombiGene has a clear strategy to identify new, promising projects and academic research collaborations, but also to find a new development partner for the epilepsy project CG01. These objectives were on the agenda when CEO Peter Ekolind presented the company at NLSDays in Malmö.
Gene therapy company CombiGene focuses primarily on developing the pain program COZY in collaboration with the Danish biotech company Zyneyro. The program includes both a peptide treatment (COZY01) and a gene therapy treatment (COZY02) to treat severe chronic nerve pain. CombiGene’s pipeline also includes CG01, a gene therapy for the treatment of severe drug-resistant focal epilepsy. The company is currently awaiting the final data generated by Spark Therapeutics.
CEO reflects on participation at NLSDays 2024
CombiGene has just discussed its projects with potential partners at the Nordic region’s largest partnering conference for the life science industry, Nordic Life Science Days (NLSDays), which took place in Malmö from September 18 to 19.
BioStock contacted CEO Peter Ekolind to get his impressions from the conference.
What strategic partnerships or collaborations are you currently seeking for CG01 and other projects that may require further development or commercialization?
– The process of finding a partner who wants to in-license one of our projects is ongoing and requires work and takes a long time. Meeting venues like NLSDays and others are a natural platform to present the company’s various projects.
You previously mentioned that receiving additional key data from Spark would enable you to define a strategy for the epilepsy project, CG01. Could you elaborate on this?
– We are in the middle of that work and cannot comment on this now. When we have finished that work and the strategy is ready, we will of course inform the market about it.
How important is NLSDays as a platform for finding potential partnership opportunities? Did your participation give you any concrete leads?
– NLSDays is one of several opportunities to meet potential takers and suppliers. I met some companies that were interested in our projects and that have received more information to analyze. The next major occasion is BIO Europe 2024, which takes place in Stockholm on 4-6 November. I am looking forward to meeting more potential partners there.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
